Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08 00 a.m. Finnish time

Nachrichtenquelle: PR Newswire (engl.)
27.11.2020, 07:19  |  145   |   |   

HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, one more non-GMP line commissioned and a new near-term business target introduced: "First Biologics PoC project in 2021".

7-9/2020 key financials:

- Revenue was EUR 159 thousand, during 7-9/2019 there were no revenues.

- The gross profit and margin came in at EUR 101 thousand and 63%, during 7-9/2019 the gross profit was negative.

- The operating loss was EUR -3.8 million (operating loss was EUR -2.1 million in 7-9/2019).

- The loss for the period was EUR -4.2 million (EUR -2.2 million in 7-9/2019).

- Basic EPS was EUR -0.06 (EUR -0.05).

- The number of employees grew to 68 at the end of 7-9/2020 (34 employees at the end of 7-9/2019).

- Cash position was EUR 66.6 million on September 30, 2020 (EUR 10.3m on September 30, 2019).

1-9/2020 key financials:

- Revenue was EUR 501 thousand and stemmed from nine different customer projects. In 1-9/2019 there were no revenues.

- The gross profit and margin came in at EUR 363 thousand and 72%, respectively. In 1-9/2019 the gross profit was EUR -182 thousand.

- The operating loss and the loss for the period were EUR -14.8 million and EUR -15.5 million, respectively. In 1-9/2019 the operating loss and the loss for the period were EUR -4.7 million and EUR -5.0 million, respectively.

- Basic EPS was EUR -0.29 (EUR -0.12).

- EUR 79.9 million (gross) was raised in the IPO.

Significant events during 1-9/2020

- In January Nanoform USA Inc. (100% owned subsidiary in the US) was established.

- In March Nanoform signed two new agreements, one with a global major pharma company and one with Orion Corporation, a repeat customer.

 - In March two new non-GMP lines were commissioned.

- On April 7, at the AGM, Miguel Calado was appointed chairman of the Board of Directors, after being vice chairman for a year.

- In April Nanoform was awarded Good Manufacturing Practices (GMP) status by the Finnish Medicines Agency, FIMEA.

-In April the Company's form was changed to a public limited liability company and the share capital was increased to EUR 80 thousand.

Seite 1 von 5


Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08 00 a.m. Finnish time HELSINKI, Nov. 27, 2020 /PRNewswire/ - Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma …

Nachrichten des Autors

Titel
Titel
Titel
Titel